Hemcheck Sweden AB has extended the evaluation agreement with Hemakim Tibbi Ürünler San.Ve Tic. A.S (”Hemakim”) to the end of May 2021. The evaluation agreement, that is now extended a second time, was formed to evaluate the collaboration and market opportunity, however the current pandemic has created challenges to get access to local hospitals delaying the evaluation. The new extension is expected to give enough time to complete the evaluation. After the extended evaluation period, the agreement can be extended into a distribution agreement with the same terms as earlier communicated.

-Both parties are in full agreement to continue and complete the evaluation that has been started but is delayed by the current pandemic. We continue to remain very positive and see potential for a long-term collaboration with Hemakim, says Joen Averstad, CEO of Hemcheck.

-We remain very positive about the potential success of the products in the Turkish market and hope to finalize the evaluation in this new extension of the evaluation agreement, says Aziz Eroglu, CEO of Hemakim.

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About Hemakim

Hemakim is a family-owned Turkish company group founded in 1983. The Group consists of several legal entities focusing on a wide number of fields such as in-vivo and in-vitro diagnostics in hospitals, immunohematology, microbiology, etc. Hemakim has its head office in Istanbul and has several regional offices and sub-dealers throughout Turkey. The group turnover is ca 50 MUSD. Hemakim is a partner to several large companies such as Thermo Scientific.

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.